Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

HCA Healthcare Collaborates with Google Cloud to Bring Generative AI to Hospitals

What You Should Know: – HCA Healthcare and Google Cloud today announced a new collaboration designed to use generative AI technology to improve workflows on

August 29, 2023

Opinion | Who Is to Blame for the Rampant Overtreatment of Peripheral Artery Disease?

Hicks is an associate professor of surgery and a director of clinical outcomes research. The recent New York Times article highlighting inappropriate treatment patterns among

August 14, 2023

Roche declares early win for oral GLP-1 drug it bought from Carmot

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.